3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
28
Breast
20
Genitourinary
18
Gastrointestinal
14
Thoracic
10
Sarcoma
6
Tumor-Agnostic
4
Other solid neoplasm
4
Endocrine
4
CNS
4
NET
3
Lymphoid
3
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Head & Neck
2
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Nasopharyngeal Carcinoma
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
Cisplatin
85
pembrolizumab
76
Magnetic Resonance Spectroscopy
46
Radiotherapy, Intensity-Modulated
41
Specimen Handling
36
Cetuximab
36
Carboplatin
35
Radiotherapy
34
Nivolumab
28
Paclitaxel
24
Radiation
22
Platinum
22
Docetaxel
20
Biopsy
20
1,2-diaminocyclohexaneplatinum II citrate
20
Gemcitabine
19
Surveys and Questionnaires
15
Fluorouracil
14
toripalimab
13
Standard of Care
12
Taxes
11
cemiplimab
9
atezolizumab
9
Ipilimumab
9
Drug Therapy
9
Cyclophosphamide
9
X-Rays
8
Surgical Procedures, Operative
8
Radiosurgery
7
Immunoglobulin G
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
olaparib
×
Head & Neck
×
90 days
×
Clear all
NCT04825990
2026-06-01
POINT
Gruppo Oncologico del Nord-Ovest
Phase 2
Active not recruiting
30 enrolled
NCT02308072
2026-05-22
ORCA-2
University College, London
Phase 1
Completed
16 enrolled